Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 162,100 shares, a decline of 12.5% from the November 15th total of 185,300 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 1,621.0 days.
Molecular Partners Stock Performance
Shares of MLLCF stock opened at $6.25 on Friday. The firm has a fifty day moving average price of $6.39 and a 200 day moving average price of $6.22. Molecular Partners has a 12 month low of $5.16 and a 12 month high of $32.00.
Get
Molecular Partners alerts:
About Molecular Partners
(Get Rating)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
Recommended Stories
- Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 162,100 shares, a decline of 12.5% from the November 15th total of 185,300 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 1,621.0 days.
分子合作伙伴股份公司(场外交易代码：MLLCF-GET Rating)是11月份空头股数价格大幅下降的接受者。截至11月30日，空头股数共有162,100股，较11月15日的185,300股下跌12.5%。以日均成交量100股计算，目前短息比率为1,621.0天。
Molecular Partners Stock Performance
Shares of MLLCF stock opened at $6.25 on Friday. The firm has a fifty day moving average price of $6.39 and a 200 day moving average price of $6.22. Molecular Partners has a 12 month low of $5.16 and a 12 month high of $32.00.
MLLCF股票周五开盘报6.25美元。该公司的50日移动平均价为6.39美元，200日移动平均价为6.22美元。Molecal Partners的12个月低点为5.16美元，12个月高位为32.00美元。
Get
Molecular Partners
alerts:
About Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
分子伙伴公司是一家临床阶段的生物制药公司，专注于治疗性蛋白质的发现、开发和商业化。它的候选产品包括用于治疗新血管湿性老年性黄斑变性和糖尿病黄斑水肿的候选DARPin药物Abempar，该药物处于第三阶段临床试验；以及针对SARS-CoV-2病毒的多特异性DARPin候选药物MP0420。
Recommended Stories
- Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- 免费获取StockNews.com关于分子伙伴的研究报告(MLLCF)
- MarketBeat：回顾一周12/12-12/16
- 哪两家蓝筹科技公司提高了他们的指引？
- 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗？
- 拖拉机库存能否突破杯柄收购点？
- 现在不是购买Lennar的时候，但时机即将到来
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到分子合作伙伴的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收分子合作伙伴和相关公司的最新新闻和分析师评级的每日摘要。
